women's health

UCSF Team Identifies Druggable Genes Related to Preterm Birth
Premium

Researchers have flagged 99 genes related to muscle contractility related to spontaneous preterm birth, along with nine potentially therapeutic drugs that target them.

Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split

Aspira Women's Health has been evaluating Dana-Farber's microRNA technology for ovarian cancer detection since early 2021.

women's health

UCSF Team Identifies Druggable Genes Related to Preterm Birth
Premium

Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split

Candel Therapeutics to Raise $80M in Public Stock and Warrants Offering

Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel

Boundless Bio Ends Trial of BBI-825 in Patients With Certain Cancer Resistance Mutations

In Brief This Week: Lantern Pharma, AstraZeneca, Genesupport, UniQure, PanGIA Biotech

Leapfrog Bio to Begin Phase II Trial of Synthetic Lethal Candidate in Solid Tumors

Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial

women's health

UCSF Team Identifies Druggable Genes Related to Preterm Birth Premium

Aspira Women's Health Licenses Dana-Farber microRNA Signature; Firm Executes Reverse Stock Split

Candel Therapeutics to Raise $80M in Public Stock and Warrants Offering

Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel

Boundless Bio Ends Trial of BBI-825 in Patients With Certain Cancer Resistance Mutations

In Brief This Week: Lantern Pharma, AstraZeneca, Genesupport, UniQure, PanGIA Biotech

Leapfrog Bio to Begin Phase II Trial of Synthetic Lethal Candidate in Solid Tumors

Natera Enrolls First Patients in Phase III SAGITTARIUS Colon Cancer Trial

UCSF Team Identifies Druggable Genes Related to Preterm Birth
Premium